Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

TRJ, TRAJAN SCIENTIFIC AND MEDICAL LIMITED
nipper
post Posted: Jun 10 2021, 05:46 PM
  Quote Post


Posts: 9,138
Thanks: 2749


In Reply To: nipper's post @ Jun 7 2021, 08:09 PM

and now $2.17 , steady incremental lift since Monday

Asked why the future of Trajan might be bright for investors, CEO Stephen Tomisich provided solid reasons:
QUOTE
Clearly I am (as a founder and CEO) investing in it, so maybe that is a good sign that we are maintaining majority shareholding. But if you look at our business history, what I like about it is its substance and underlying resilience.

We have 80 to 85 per cent of our revenues in recurring revenues, and those have proven to be resilient even right through COVID.


QUOTE
Unlike many healthcare stocks, it is not a case of make or break with Trajan. We have a very healthy economic engine that underpins the business, but we still have the upside of that entrepreneurial and disruptive approach to new technology development, and I think it's the combination of those that excites me about the business.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Jun 7 2021, 08:09 PM
  Quote Post


Posts: 9,138
Thanks: 2749


In Reply To: nipper's post @ May 18 2021, 03:21 PM

TRJ listed today, opened and held above $1.90 during the day to close at $1.98 (IPO at $1.70)

The founders have no intention of selling down more than was released into the float ($40M), keeping their holding at 59%.

The key products of Trajan include a range of items that facilitate the chemical separation of components in a sample, such as microscope slides and coverslips, and analytical syringes. The company had made seven acquisitions before the IPO, and is eyeing more targets, which is part of the reason it tapped public markets.
QUOTE
Proceeds will also be used for manufacturing modernisation to drive margin gains and accelerate commercialisation of new technologies such as its hemaPEN micro blood sampling device and a miniaturised instrumentation that is now the prototype inside major US pharma players working on how to monitor the next generation of pharmaceutical manufacturing.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 18 2021, 03:21 PM
  Quote Post


Posts: 9,138
Thanks: 2749


Trajan Scientific & Medical Ltd (TRJ) has a prospectus currently doing the rounds, looking to raise $90million at $1.70. The offer is open for another week and Trajan is likely to list on ASX on 07 June 2021. Its primary focus will be the development and manufacture of analytical and life sciences instruments and devices

Trajan's operations were initiated by the acquisition of two pathology consumables businesses in 2011 and 2013.

In 2013, Trajan made the significant acquisition of the chromatography and liquid handling businesses of SGE Analytical Science, a business operating in the highly specialised analytical syringe sector, as well as having a range of other chromatography products.

In 2015, Trajan made the strategic decision to focus its core expertise and operations on where it could impact data quality, being everything that touches the sample in the analytical workflow. Trajan invested significantly in the modernisation of its manufacturing processes and relocated its US and European operations into modern, custom‑fitted facilities, as it did with workflow automation provider LEAP Technologies, Inc. , which was acquired in 2016.

Trajan has operations in Australia and across the United States (US), Europe and Asia.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING